文献速递白血病造血干细胞移植与细胞治疗

诱导后微小残留病灶预测NPM1突变急性髓系白血病结局及异基因干细胞移植获益:急性白血病法国协会组研究

Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group.
PubMed 文献 · J Clin Oncol · 2016-11-14

在ALFA-0702试验229例NPM1突变急性髓系白血病患者中,152例首次缓解期可评估微小残留病灶。诱导后外周血NPM1突变微小残留病灶未达4-log降低者复发累积发生率更高、总生存更短,且该指标可预测异基因干细胞移植获益。

要点

  • 诱导后外周血NPM1突变微小残留病灶未达4-log降低者复发风险更高、总生存更短。
  • 在ELN非良好风险患者中,外周血微小残留病灶未达4-log降低者接受异基因干细胞移植可改善无病生存和总生存。
  • 外周血微小残留病灶达4-log以上降低者未观察到异基因干细胞移植获益,移植效应与微小残留病灶反应存在显著交互作用。

核心结论

  • 本研究支持早期外周血NPM1突变微小残留病灶具有强预后意义,且独立于细胞遗传学和分子学背景。
  • 外周血NPM1突变微小残留病灶可能用作异基因干细胞移植指征的预测因素。

研究设计与样本

  • 急性白血病法国协会0702(ALFA-0702)试验中229例NPM1突变急性髓系白血病患者,年龄18至60岁。
  • 152例首次缓解期患者可评估微小残留病灶。
  • 根据欧洲白血病网(ELN)分类为非良好风险的患者在首次缓解期符合异基因干细胞移植条件。

主要发现

  • 诱导治疗后外周血NPM1突变微小残留病灶未达4-log降低者复发累积发生率更高(亚风险比[SHR] 5.83;P < .001),总生存更短(风险比[HR] 10.99;P < .001)。
  • 多变量分析中,异常核型、FLT3内部串联重复(ITD)阳性及外周血微小残留病灶<4-log降低与更高的复发发生率和更短的总生存显著相关。
  • 在FLT3-ITD患者亚组中,仅年龄、白细胞计数和外周血微小残留病灶<4-log降低保持显著预后价值,FLT3-ITD等位基因比值无显著预后价值。
  • 在ELN非良好风险且外周血微小残留病灶<4-log降低的患者中,异基因干细胞移植显著改善无病生存和总生存。
  • 在外周血微小残留病灶>4-log降低的患者中未观察到该获益,移植效应与微小残留病灶反应间存在显著交互作用(无病生存P = .024,总生存P = .027)。

关键数值与推荐

  • 外周血微小残留病灶未达4-log降低者复发亚风险比5.83(P < .001),总生存风险比10.99(P < .001)。
  • 移植效应与微小残留病灶反应交互作用:无病生存P = .024,总生存P = .027。

临床怎么用

  • 作者认为早期外周血NPM1突变微小残留病灶具有强预后意义,可能用作异基因干细胞移植指征的预测因素。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose This study assessed the prognostic impact of postinduction NPM1-mutated ( NPM1m) minimal residual disease (MRD) in young adult patients (age, 18 to 60 years) with acute myeloid leukemia, and addressed the question of whether NPM1m MRD may be used as a predictive factor of allogeneic stem cell transplantation (ASCT) benefit. Patients and Methods Among 229 patients with NPM1m who were treated in the Acute Leukemia French Association 0702 (ALFA-0702) trial, MRD evaluation was available in 152 patients in first remission. Patients with nonfavorable AML according to the European LeukemiaNet (ELN) classification were eligible for ASCT in first remission. Results After induction therapy, patients who did not achieve a 4-log reduction in NPM1m peripheral blood-MRD (PB-MRD) had a higher cumulative incidence of relapse (subhazard ratio [SHR], 5.83; P < .001) and a shorter overall survival (OS; hazard ratio [HR], 10.99; P < .001). In multivariable analysis, an abnormal karyotype, the presence of FLT3-internal tandem duplication (ITD), and a < 4-log reduction in PB-MRD were significantly associated with a higher relapse incidence and shorter OS. In the subset of patients with FLT3-ITD, only age, white blood cell count, and < 4-log reduction in PB-MRD, but not FLT3-ITD allelic ratio, remained of significant prognostic value. In these patients with nonfavorable AML according to European LeukemiaNet, disease-free survival and OS were significantly improved by ASCT in those with a < 4-log reduction in PB-MRD. This benefit was not observed in those with a > 4-log reduction in PB-MRD, with a significant interaction between ASCT effect and PB-MRD response ( P = .024 and .027 for disease-free survival and OS, respectively). Conclusion Our study supports the strong prognostic significance of early NPM1m PB-MRD, independent of the cytogenetic and molecular context. Moreover, NPM1m PB-MRD may be used as a predictive factor for ASCT indication.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Balsat M, Renneville A, Thomas X, et al. Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group. J Clin Oncol. 2016. PMID: 28056203

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。